<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591343</url>
  </required_header>
  <id_info>
    <org_study_id>101-PG-PSC-186</org_study_id>
    <nct_id>NCT01591343</nct_id>
  </id_info>
  <brief_title>Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma</brief_title>
  <official_title>Prospective Study to Evaluate the Safety of a 4-month Treatment With Depigoid® Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml) in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Mild Persistent or Intermittent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Leti, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harrison Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Leti, S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides&#xD;
      pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or&#xD;
      rhinoconjunctivitis with or without asthma.&#xD;
&#xD;
      Primary variable: number of subjects [%] who experienced at least one immediate or delayed&#xD;
      systemic reaction of EAACI grade 2 or higher during the 4-month treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator(s):&#xD;
&#xD;
      Approximately 10 study centers (allergy services) in Spain&#xD;
&#xD;
      Planned study period:&#xD;
&#xD;
      MAY 2012 (first subject in) - MAR 2013 (last subject out)&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective: to evaluate the safety of a 4-month treatment with an extract of Depigoid®&#xD;
      Dermatophagoides pteronyssinus or a mixture of 50% Dermatophagoides pteronyssinus and 50%&#xD;
      Dermatophagoides farinae at a concentration of 500 DPP/ml administered following a rush&#xD;
      build-up regimen.&#xD;
&#xD;
      Secondary objective: to assess the subjects' immunologic responses to the above treatment.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      This is a prospective, non-randomized, uncontrolled, open-label safety study. When the first&#xD;
      29 subjects have completed the study, an interim analysis will be conducted to check whether&#xD;
      the number of systemic reactions in these subjects is below a predefined limit.&#xD;
&#xD;
      Planned number of subjects:&#xD;
&#xD;
      103 subjects in total.&#xD;
&#xD;
      Medical condition or disease under investigation:&#xD;
&#xD;
      Allergic rhinitis or rhinoconjunctivitis, with or without mild persistent or intermittent&#xD;
      asthma.&#xD;
&#xD;
      Test product, dose and mode of administration:&#xD;
&#xD;
      Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).&#xD;
&#xD;
      Dose: Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of&#xD;
      administration: subcutaneous injection&#xD;
&#xD;
      Duration of treatment:&#xD;
&#xD;
      16 weeks.&#xD;
&#xD;
      Criteria for evaluation:&#xD;
&#xD;
      Safety:&#xD;
&#xD;
      Local and systemic adverse reactions (EAACI classification); adverse events.&#xD;
&#xD;
      Efficacy:&#xD;
&#xD;
      Immunologic response to the treatment.&#xD;
&#xD;
      Statistical methods:&#xD;
&#xD;
      Primary variable: number of subjects [%] who experienced at least one immediate or delayed&#xD;
      systemic reaction of EAACI grade 2 or higher during the 4-month treatment period.&#xD;
&#xD;
      Analysis of primary variable: exact binomial test&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study halted by Sponsor&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary variable</measure>
    <time_frame>4 months</time_frame>
    <description>Number of subjects [%] who experienced at least one immediate or delayed systemic reaction of EAACI grade 2 or higher during the 4-month treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary variables</measure>
    <time_frame>4 months</time_frame>
    <description>Secondary variables, which will be analyzed descriptively, are the&#xD;
Number of subjects [%] suffering immediate and/or delayed systemic reactions broken down by grade (EAACI classification).&#xD;
Number of subjects [%] suffering immediate and/or delayed local reactions broken down by diameter (&lt; 5 cm, 5-10 cm or &gt; 10 cm).&#xD;
Number of immediate and/or delayed systemic reactions broken down by grade (EAACI classification).&#xD;
Number of immediate and/or or delayed local reactions broken down by diameter (&lt; 5 cm, 5-10 cm and &gt; 10 cm).&#xD;
Immunologic response to the treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Mild Persistent Asthma</condition>
  <condition>Mild Intermittent Asthma</condition>
  <arm_group>
    <arm_group_label>Depigoid® (500 DPP/ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Depigoid® (500 DPP/ml)</intervention_name>
    <description>Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).&#xD;
Dose:&#xD;
Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection</description>
    <arm_group_label>Depigoid® (500 DPP/ml)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women between 18 and 55 years of age (both inclusive).&#xD;
&#xD;
          -  Individuals suffering symptoms of allergic rhinoconjunctivitis or rhinitis during at&#xD;
             least the preceding year -- with or without symptoms of mild persistent or&#xD;
             intermittent allergic asthma which is controlled with a dose less or equal to 400&#xD;
             µg/day budesonide or an equivalent -- caused by a clinically relevant sensitization to&#xD;
             house dust mites (Dermatophagoides pteronyssinus or Dermatophagoides pteronyssinus and&#xD;
             Dermatophagoides farinae).&#xD;
&#xD;
          -  The IgE-mediated sensitization will be demonstrated by means of the following: medical&#xD;
             history and IgE specific to house dust mites (D. pteronyssinus or D. pteronyssinus and&#xD;
             D. farinae) CAP RAST ≥ 2 and positive skin prick test. A skin prick test will be&#xD;
             considered positive when it produces a wheal of at least 3 mm according to the largest&#xD;
             diameter.&#xD;
&#xD;
          -  Asthmatic patients must be stable and on a stable inhaled steroid dose within 6 weeks&#xD;
             prior to visit 1 and throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication for treatment with allergen specific immunotherapy.&#xD;
&#xD;
          -  Forced expiratory volume in 1 s (FEV1) or peak expiratory flow (PEF) value &lt; 80% of&#xD;
             the predicted normal value.&#xD;
&#xD;
          -  Allergy symptoms due to sensitization to pollens or other perennial allergens (molds,&#xD;
             epithelia).&#xD;
&#xD;
          -  Subjects with typical symptoms to co-allergens such as tree pollen, grasses or weeds,&#xD;
             fungi or animal epithelial cells cannot participate in this study. Patients sensitized&#xD;
             to pollens with specific IgE CAP RAST &lt; 2 can be included in this study provided that&#xD;
             they do not present symptoms as a consequence of this sensitization. Patients&#xD;
             sensitized to animal epithelia who do not present symptoms can participate in this&#xD;
             study provided that they are not exposed to the allergen to which they are sensitized,&#xD;
             even though they present specific IgE with CAP RAST ≥ 2. If they were exposed to the&#xD;
             animal in question, these subjects must have a specific IgE with CAP RAST &lt; 2 in order&#xD;
             to participate in the study.&#xD;
&#xD;
          -  Asthma requiring a dose &gt; 400 µg/day of Budesonide or an equivalent, without&#xD;
             long-lasting beta-2 agonists, to reach control according to the Global Initiative for&#xD;
             Asthma (GINA 2010).&#xD;
&#xD;
          -  Patients with non controlled bronchial asthma within 3 months prior to Visit 1.&#xD;
&#xD;
          -  Patients with asthma who have been treated with systemic steroids within 3 months&#xD;
             prior to V1.&#xD;
&#xD;
          -  Patients with hospital admission due to asthma exacerbations within 1 year prior to V1&#xD;
&#xD;
          -  Acute or chronic inflammatory or infectious diseases of the airways.&#xD;
&#xD;
          -  Chronic structural diseases of the respiratory system (for example, emphysema or&#xD;
             bronchiectasis).&#xD;
&#xD;
          -  Immune system diseases, both autoimmune diseases and immunodeficiency.&#xD;
&#xD;
          -  Any disease involving a contraindication for the use of adrenaline (for example,&#xD;
             hyperthyroidism).&#xD;
&#xD;
          -  Serious uncontrolled diseases involving a risk for the subjects participating in this&#xD;
             study, including the following for example: heart failure, serious or uncontrolled&#xD;
             respiratory diseases, endocrine diseases, clinically relevant liver or kidney diseases&#xD;
             or hematological diseases.&#xD;
&#xD;
          -  Malignant disease with activity in the last 5 years.&#xD;
&#xD;
          -  Clinically significant anomaly in laboratory parameters or vital signs which could&#xD;
             involve a risk increase for the subject.&#xD;
&#xD;
          -  Excessive consumption of alcohol, drugs or medication in the preceding year.&#xD;
&#xD;
          -  Serious psychiatric, psychological or neurological disorders.&#xD;
&#xD;
          -  Use of immunotherapy with allergenic extracts of storage or house dust mites in the&#xD;
             last 5 years.&#xD;
&#xD;
          -  Systemic or topical treatment with beta-blocker drugs.&#xD;
&#xD;
          -  Treatment with substances interfering with the immune system 2 weeks before visit 2.&#xD;
&#xD;
          -  Use of psychotropic or antidepressants substances.&#xD;
&#xD;
          -  Use of systemic corticosteroids 3 months before visit 1.&#xD;
&#xD;
          -  Immunization with prophylactic (bacterial or viral) vaccines within 7 days before&#xD;
             visit 2. (Prophylactic vaccines are allowed during the administration of IMP period&#xD;
             provided they are administered at least one week after immunotherapy and the next&#xD;
             immunotherapy dose is administered at least 14 days later).&#xD;
&#xD;
          -  Participation of the subject in another clinical trial 30 days before visit 2.&#xD;
&#xD;
          -  Subjects who have already participated in this clinical trial.&#xD;
&#xD;
          -  Subjects who are going to donate stem cells, blood, organs or bone marrow in the&#xD;
             course of the study.&#xD;
&#xD;
          -  Female subjects who are pregnant or nursing and women with a positive pregnancy test&#xD;
             at visit 1 or 2.&#xD;
&#xD;
          -  Women of childbearing potential not using highly effective methods of birth control.&#xD;
             Highly effective methods of birth control are defined as those which result in a low&#xD;
             failure rate (i.e. less than 1% per year) when used consistently and correctly, such&#xD;
             as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence&#xD;
             or vasectomized partner. Female patients will be considered to be of childbearing&#xD;
             potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or&#xD;
             post-menopausal for at least two years.&#xD;
&#xD;
          -  No written informed consent upon enrolment.&#xD;
&#xD;
          -  Not willing to give consent for transmission of personal &quot;pseudonymised&quot; data.&#xD;
&#xD;
          -  Subjects who are unable to comply with the requirements of the study or who in the&#xD;
             opinion of the investigator should not participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <state>Andalucía</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Doctor Lobatón</name>
      <address>
        <city>Cádiz</city>
        <state>Andalucía</state>
        <zip>11008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospita Universitario Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al·lergo Centre</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Teknon</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <state>Cataluña</state>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Cartagena</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>03020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>May 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Specific immunotherapy</keyword>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Allergic rhinoconjunctivitis</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

